+ND Capital's European Investment Strategy Delivers Again as Sale of CellPoint to Galapagos Paves the Way for Disruptive Point-of-Care Cell Therapy Model for Cancer Patients
Lausanne-based +ND Capital's investment strategy delivers again as Galapagos acquires CellPoint for €125m cash upfront and up to €100m in milestone paymentsPotential for paradigm shift in CAR-T therapy with CellPoint's decentralized point-of-care manufacturing model, in collaboration with Basel-based LonzaAs sole venture investor in CellPoint, the sale underlines +ND Capital's success in Europe, being its second exit after Arctos Medical sale to NovartisWOODSIDE, Calif. and LAUSANNE, Switzerland, June 21, 2022 /PRNewswire/ -- The Lausanne-based team of US investment firm, +ND Capital, today marked its second successful exit in the European biotechnology market as Belgian biotech company, Gal
